Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755867 · ClinicalTrials.gov registry record
Global PNH Patient Registry
A clinical trial of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Aplastic Anemia and MDS International Foundation.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05755867 is a study of Paroxysmal Nocturnal Hemoglobinuria that is actively recruiting participants, run by Aplastic Anemia and MDS International Foundation. The registered enrollment target is 500 participants, above the 229-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (118% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05755867, a study of Paroxysmal Nocturnal Hemoglobinuria, is actively recruiting participants, sponsored by Aplastic Anemia and MDS International Foundation.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry is to conduct a prospectively-planned and efficient natural history study that will result in a more comprehensive understanding of the disease and its course and pace over time. Other registry objectives include the following: * Provide a convenient online platform for participants (or caregivers) to self-report cases of PNH. * Develop a communications registry within the Global PNH Patient registry (e.g., to notify patients of research studies and clinical trials). * Characterize and describe the Global PNH population as a whole, enhancing the understanding of disease prevalence and phenotype as well as the rate of progression of disease characteristics. * Assist the PNH community with the development of recommendations and standards of care. * Be a case-finding resource to be used for researchers who seek to study the pathophysiology of PNH, retrospectively collate intervention outcomes, and design prospective trials of novel treatments.
Conditions Studied
Study Locations (1)
Maryland
- Aplastic Anemia and MDS International Foundation - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2031-05-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05755867
The ClinicalTrials.gov registry entry for NCT05755867 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 229-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (118% higher). The listed sponsor is Aplastic Anemia and MDS International Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 0 interventions.
NCT05755867 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05755867 about?
NCT05755867 is a clinical study titled "Global PNH Patient Registry". The primary aim of the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry is to conduct a prospectively-planned and efficient natural history study that will result in a more comprehensive understanding of the disease and its course and pace over time. Other registry objectives includ...
What is the current status of trial NCT05755867?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-05-06. Estimated completion is 2031-05-06.
What conditions does trial NCT05755867 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria.
Who is sponsoring clinical trial NCT05755867?
This trial is sponsored by Aplastic Anemia and MDS International Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05755867 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The International PNH Interest Group PNH Registry
RECRUITING
-
Home Reported Outcomes in PNH
RECRUITING
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RECRUITING · Phase 2
-
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
ACTIVE NOT RECRUITING
-
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.